Abstract
The evaluation of tongue swellings often represents a diagnostic challenge, because of the wide spectrum of benign and malignant possible lesions. We report a case of a patient presenting a tongue mass. An incisional biopsy was performed. Diagnosis of primary Mantle Cell non-Hodgkin’s Lymphoma of the tongue was made by histological, immunohistochemical and cytogenetic studies. Our patient was treated with Rituximab–Cyclophosphamide, Epirubicine, Vincristine, Prednisone polychemotherapy plus Rituximab as single agent maintenance. Complete remission was achieved and no relapse has occurred during a follow-up of 53 months. We emphasize the importance of including also NHL in differential diagnosis of a tongue mass.
Similar content being viewed by others
References
Epstein JB, Epstein JD, Le ND, Gorsky M. Characteristics of oral and paraoral malignant lymphoma: a population-based review of 361 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;92:519–25.
Van der Waal RIF, Huijgens PC, van der Valk P, van der Waal I. Characteristics of 40 primary extranodal non-Hodgkin lymphomas of the oral cavity in perspective of the new WHO classification and the International Prognostic Index. Int J Oral Maxillofac Surg. 2005;34:391–5.
Haidar Z. A review of non-Hodgkin’s lymphoma of the oral cavity 1950–1980. J Oral Med. 1986;41:197–200.
Shima N, Kobashi Y, Tsutsui K, et al. Extranodal non-Hodgkin’s lymphoma of the head and neck. A clinicopathologic study in the Kyoto-Nara area of Japan. Cancer. 1990;66:1190–7.
Domanski HA, Akerman M. Fine-needle aspiration cytology of tongue swellings: a study of 75 cases. Diagn Cytopathol. 1998;18:387–92.
Touboul E, Ghenim C, Chantelar JV, et al. Non-Hodgkin lymphomas of the head and neck, stages I and II. A propos 35 cases. Rev Stomatol Chir Maxillofac. 1985;86:300–9.
Derk CT, Conway RT, Jimenez SA. Primary B-cell lymphoma of the tongue in a patient with systemic sclerosis. Oral Oncol. 2004;40:103–6.
Van der Waal RIF, Pas HH. Paraneoplastic pemphigus as the presenting symptom of a lymphoma of the tongue. Oral Oncol. 1998;34:567–70.
Sakabe H, Bamba M, Nomura K, et al. MALT lymphoma at the base of the tongue developing without any background of immunodeficiency or autoimmune disease. Leuk Lymphoma. 2003;44:875–8.
Menarguez J, Mollejo M, Carrion R, et al. Waldeyer’s ring lymphoma. A clinicopathological study of 79 cases. Histopathology. 1994;24:13–22.
Zinzani PL, Magagnoli L, Galieni P, et al. Non gastro-intestinal low-grade mucosa associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol. 1999;17:1254–8.
Piattelli A, Di Alberti L, Artese L. Non-hodgkin’s lymphoma of the tongue: a case report. Eur J Cancer B Oral Oncol. 1996;32:207–9.
Manolopoulos L, Nikolopoulos TP, Yiotakis J, Karapatsas J, Maris A, Ferekidis E. Burkitt’s lymphoma in the base of the tongue: differential diagnosis and management. ORL J Otorhinolaryngol Relat Spec. 2003;65:226–9.
Yoskovitch A, Hier MP, Begin LR, et al. Dorsal tongue mass. Oral Sur Oral Med Oral Pathol Oral Radiol Endod. 2000;90:5–8.
Ezzat AA, Ibrahim EM, El Weshi AN, et al. Localized non-Hodgkin’s lymphoma of Waldeyer’s ring: clinical features, management, and prognosis of 130 adult patients. Head Neck. 2001;23:547–58.
The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s Lymphoma. Blood. 1997;89:3909–18.
Saxman S, Righi P. Mantle cell lymphoma appearing as a tongue base mass. Ear Nose Throat J. 1997;76:35–6.
Thorns C, Bier B, Feller AC. Multilobated mantle cell lymphoma. Leuk Lymphoma. 2006;47:770–2.
Gill S, Ritchie D. Therapeutic options in mantle cell lymphoma. Leuk Lymphoma. 2008;49:398–409.
Rosenbluth BD, Yahalom J. Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy. Int J Radiat Oncol Biol Phys. 2006;65:1185–91.
Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin oncology Network. Ann Oncol. 2006;17:1418–23.
Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration aftere salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003–8.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Guastafierro, S., Falcone, U., Celentano, M. et al. Primary mantle-cell non-Hodgkin’s lymphoma of the tongue. Int J Hematol 88, 206–208 (2008). https://doi.org/10.1007/s12185-008-0142-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-008-0142-z